Sabril - Vigabatrin

A different approach led to the development of vigabatrin (Sabril). Its ability selectively and irreversibly to inhibit GABA-transaminase from metabolically inactive GABA (as a suicide inhibitor) makes it an effective agent (Fig. 12-5), particularly in complex partial seizures. 

Treatment has been attempted with y-vinyl GABA (vigabatrin, Sabril ), an inhibitor of GABA transaminase, in order to reduce substrate accumulation [6]. This resulted in a decrease of CSF y-hydroxybutyric acid levels and improvement of cerebellar signs in a majority of patients. 

When there is a suspicion of SSD deficiency, a trial with vigabatrin (Sabril) 50-100 mg/kg/day (divided in two daily doses) is indicated. In most patients this treatment improves cerebellar signs. 

Hawker MJ, Astbury NJ. The ocular side effects of vigabatrin (Sabril) information and guidance for screening. Eye (Lond)... 

---